The negotiated prices of 15 Medicare Part D drugs, which include several blockbusters, will go into effect in 2027.

Although Pfizer is not among the drugmakers suing the government to block negotiations, it has said the program will hinder drug R&D and innovation.

Many dog owners have already heard about the FDA warning and seen the articles on the terrible side effects experienced by ...

These companies headline a $1.4 trillion industry, have staying power, and will pay you well to hold their stock.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Bernstein analyst Courtney Breen maintained a Hold rating on Pfizer (PFE – Research Report) today and set a price target of $32.00. The ...

Obesity continues to grab attention at the J.P. Morgan Healthcare Conference in San Francisco, with both Pfizer and Kailera ...

Citi analyst Geoff Meacham maintained a Hold rating on Pfizer (PFE – Research Report) today. The company’s shares closed yesterday at ...

Welcome to day 1 of the J.P. Morgan Healthcare Conference, the industry's most significant dealmaking event each year.  | For ...

Enhanced mitophagy has been recognized as crucial mechanism to sustain cellular homeostasis in hypoxic tumors. Here, this group fabricates an azocalix[4]arene-modified supramolecular albumin ...

With the recent rise of diseases, pharmaceutical companies are pushing boundaries in medicine, from life-saving treatments to ...

High-yield dividend stocks may not appeal to some investors. However, if you're among those investors looking for income, ...